Insurance Coverage and Processing Labelling Webinar 
Pharmacy Times
JULY 1, 2025
SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Additionally, tafamidis stands out compared with other TTR stabilizers that are used off-label and require monitoring for renal and gastrointestinal AEs.
Pharmacy Times
JULY 22, 2025
Personalized drug selection can lead to faster symptom control, fewer hospitalizations, and improved adherence—all of which contribute to better outcomes and a more streamlined care process. Real-World Evidence, Emerging Therapies, and Demonstrating Value Technological advances are accelerating this progress.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 16, 2025
The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. Second, it does not address the core issues of higher prices, such as the use of rebates by insurers.
Pharmaceutical Technology
JULY 14, 2025
Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock. Give your business an edge with our leading industry insights.
Pharmaceutical Technology
JULY 22, 2025
It is important for the patients we serve that Sarepta maintains a productive and positive working relationship with FDA, and it became obvious that maintaining that productive working relationship required this temporary suspension while we address any questions that FDA may have and complete the Elevidys label supplement process.”
pharmaphorum
JULY 7, 2025
Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
Pharmaceutical Technology
JULY 17, 2025
July 17, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The announcement included updates on Elevidys’ label changes for Duchenne muscular dystrophy treatment. It also announced an update regarding its Elevidys label changes for Duchenne muscular dystrophy (DMD) treatment. Credit: luchschenF/Shutterstock.com.
Expert insights. Personalized for you.
Let's personalize your content